// App-Quantinova.ai

1349 : Systematic deconvolution of kinase inhibitor profiles identifies synthetic lethal targets in ERBB2-mutant and BRD4-NUT rearranged cancer

Researchers

Presenter

  • Johannes Braegelmann

Principal Investigators

  • Peter Habenberger

  • Felix Dietlein

  • Johannes M. Heuckmann

  • Sascha Menninger

  • Uwe Koch

  • Axel Choidas

  • Daniel Rauh

  • Bert Klebl

  • Martin L. Sos

  • Roman K. Thomas

Medical Centers

  • Molecular Oncology & Department of Translational Genomics, Cologne, Germany

  • Lead Discovery Center, Dortmund, Germany

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • NEO New Oncology AG, Cologne, Germany

  • Department of Chemistry and Chemical Biology, Technical University of Dortmund, Dortmund, Germany

  • Department of Translational Genomics, Cologne, Germany.

Locations

  • Germany

Companies

  • Lead Discovery Cente

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved